Ratings by Wolfe Research (Tim Anderson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/22/2023 | Merck | MRK | Upgrade | Outperform (Peerperform) |
109.07 (130.72) |
19.85% | Details | |
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Peerperform (N/A) |
|
Details | ||
| 8/5/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Novartis | NVS | Downgrade | Peerperform (Outperform) |
86.21 (99.06) |
14.91% | Details | |
| 5/1/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/5/2022 | Hub Group | HUBG | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Maintain | Peerperform (N/A) |
|
Details | ||
| 11/3/2021 | Amgen | AMGN | Maintain | Peerperform (N/A) |
|
Details | ||
| 11/3/2021 | Pfizer | PFE | Maintain | Peerperform (N/A) |
|
Details | ||
| 11/1/2021 | Hub Group | HUBG | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2021 | Merck | MRK | Maintain | Peerperform (N/A) |
|
Details | ||
| 5/6/2021 | Hub Group | HUBG | Maintain | Outperform (N/A) |
|
Details | ||
| 2/18/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2020 | Eli Lilly | LLY | Upgrade | Outperform (Peerperform) |
158.00 (724.87) |
358.78% | Details | |
| 8/21/2020 | Biogen | BIIB | Maintain | Peerperform (N/A) |
|
Details | ||
| 6/12/2020 | Merck | MRK | Downgrade | Peerperform (Outperform) |
76.74 (130.72) |
70.34% | Details | |
| 6/1/2020 | Pfizer | PFE | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/31/2020 | Regeneron Pharma | REGN | New Coverage | Peerperform (N/A) |
473.00 (890.68) |
88.3% | Details | |
| 3/31/2020 | Gilead Sciences | GILD | New Coverage | Peerperform (N/A) |
75.93 (65.27) |
-14.04% | Details | |
| 3/31/2020 | Biogen | BIIB | New Coverage | Peerperform (N/A) |
316.13 (202.46) |
-35.96% | Details | |
| 3/31/2020 | Amgen | AMGN | New Coverage | Peerperform (N/A) |
208.48 (269.38) |
29.21% | Details | |
| 11/4/2019 | Abbvie | ABBV | Maintain | Peerperform (N/A) |
|
Details | ||
| 11/1/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/31/2019 | Pfizer | PFE | Maintain | Peerperform (N/A) |
|
Details | ||
| 10/31/2019 | Hub Group | HUBG | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2019 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/24/2019 | Eli Lilly | LLY | Maintain | Peerperform (N/A) |
|
Details | ||
| 6/27/2019 | Abbvie | ABBV | Upgrade | Peerperform (Underperform) |
68.00 (94.59) |
39.1% | Details | |
| 5/1/2019 | Hub Group | HUBG | Maintain | Outperform (N/A) |
|
Details | ||
| 5/1/2019 | Pfizer | PFE | Maintain | Peerperform (N/A) |
|
Details | ||
| 5/1/2019 | Eli Lilly | LLY | Maintain | Peerperform (N/A) |
|
Details | ||
| 5/1/2019 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2018 | Pfizer | PFE | New Coverage | Peerperform (N/A) |
44.37 (25.26) |
-43.07% | Details | |
| 10/23/2018 | Merck | MRK | New Coverage | Outperform (N/A) |
72.57 (130.72) |
80.13% | Details | |
| 10/23/2018 | GlaxoSmithKline | GSK | New Coverage | Peerperform (N/A) |
40.50 (40.91) |
1.01% | Details | |
| 10/23/2018 | Eli Lilly | LLY | New Coverage | Peerperform (N/A) |
112.03 (724.87) |
547.03% | Details | |
| 10/23/2018 | Bristol-Myers Squibb Co. | BMY | New Coverage | Outperform (N/A) |
50.88 (44.70) |
-12.15% | Details | |
| 10/23/2018 | AstraZeneca | AZN | New Coverage | Outperform (N/A) |
39.49 (75.03) |
90% | Details | |
| 10/23/2018 | Abbvie | ABBV | New Coverage | Underperform (N/A) |
84.27 (68.00) |
-19.31% | Details |
